Collegium Provides Update on FDA Review of Xtampza(TM) ER, an Abuse-Deterrent Analgesic for the Treatment of Chronic Pain
October 12, 2015 at 16:15 PM EDT
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that the U.S. Food and Drug Administration (FDA) has advised Collegium ...
